Skip to main content
Fig. 6 | Stem Cell Research & Therapy

Fig. 6

From: The high level of IL-1β in the serum of ACLF patients induces increased IL-8 expression in hUC-MSCs and reduces the efficacy of hUC-MSCs in liver failure

Fig. 6

The potential mechanism by which ACLF patient serum affects the therapeutic effect of hUC-MSCs on liver failure. IL-1β was significantly higher in the serum of dead ACLF patients than in the serum of surviving ACLF patients. The high level of the inflammatory factor IL-1β in serum from dead ACLF patients can promote the expression of IL-8 in hUC-MSCs through the NF-κB signaling pathway, thereby reducing the effect of hUC-MSCs in the treatment of liver failure.The figure was drawn by the author of this study (DPI:300)

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512